netFormulary
 Report : Medicines with links to NICE 20/06/2019 04:05:07

[Back]

Report looks at the links table and pulls back all the items in the formulary where there is a link with 'nice.org' in the URL

You can sort this table Medicines Link Name or Link URL by clicking on the title

Selecting the Medicine name will take you to the entry in the formulary, Selecting the Link name will follow the link

 
Medicines/Item Section Status Link Name / Link URL
Abiraterone 08.03.04.02 Non Formulary NICE TA259 (June 2012): Abiraterone for castration resistant metastatic prostrate cancer previously treated with a docetaxel-containing regimen
Abiraterone 08.03.04.02 Non Formulary NICE TA387 (April 2016): Abiraterone for treating metastatic hormone-relapsed prostate cancer beofre chemotherapy is indicated
Adalimumab (biosimilar) 13.05.03 Restricted Use NICE TA146: Psoriasis - adalimumab
Adalimumab (biosimilar) 13.05.03 Restricted Use NICE TA392 (June 2016): Adalimumab for treating moderate to severe hidradenitis suppurativa
Adefovir dipivoxil tablets 05.03.03.01 Formulary NICE TA96 (February 2006): Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B
Agomelatine 04.03.04 Non Formulary NICE TA231: Depression - agomelatine
Alendronic Acid with Colecalciferol 06.06.02 Non Formulary CKS (March 2016): Osteoporosis - prevention of fragility fractures
Alendronic Acid with Colecalciferol 06.06.02 Non Formulary TA161 (October 2008): Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention or osteoporotic fragility fractures in postmenopausal women
Alendronic Acid with Colecalciferol 09.06.04 Non Formulary NICE TA161 (October 2008): Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teripartide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Alendronic Acid with Colecalciferol 09.06.04 Non Formulary NICE CKS (March 2016): Osteoporosis - prevention of fragility fractures
Alirocumab solution for injection 02.12 Formulary NICE TA393 (June 2016): Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Alitretinoin 13.05.01 Restricted Use NICE TA177: Eczema (chronic) - alitretinoin
Alteplase 02.10.02 Formulary NICE TA264 (26 September 2012): Alteplase for treating acute ischaemic stroke
Apixaban Tablets 02.08.02 Formulary NICE TA245 (January 2012): Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults
Apixaban Tablets 02.08.02 Formulary NICE TA341 (June 2015): Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Apixaban Tablets 02.08.02 Formulary NICE CG182 (July 2014): Chronic kidney disease in adults: assessment and management.
Apixaban Tablets 02.08.02 Formulary NICE TA275 (February 2013): Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban
Apremilast 10.01.03 Formulary NICE TA433 (February 2017): Apremilast for treating active psoriatic arthritis
Apremilast 10.01.03 Formulary NICE TA419 (November 2016): Apremilast for treating moderate to severe plaque psoriasis
Aripiprazole 04.02.01 Formulary NICE TA213: Schizophrenia - aripiprazole
Azacitidine 08.01.03 Non Formulary NICE TA218: Myelodysplastic syndromes - azacitidine
Baricitinib 10.01.03 Formulary NICE TA466 (August 2017): Baricitinib for moderate to severe rheumatoid arthritis
Bee and Wasp Allergen Extracts 03.04.02 Non Formulary NICE TA246: Venom anaphylaxis - immunotherapy pharmalgen
Belimumab 10.01.03 Formulary NICE TA397 (June 2016): Belimumab for treating autoantibody-positive systemic lupus erythematosus
Bendamustine 08.01.01 Restricted Use NICE TA206: Lymphoma (non-Hodgkins) - bendamustine (terminated appraisal)
Bendamustine 08.01.01 Restricted Use NICE TA216: Leukaemia (lymphocytic) - bendamustine
Bevacizumab 08.01.05 Non Formulary NICE TA 214: Breast cancer - bevacizumab (in combination with a taxane):
Bevacizumab 08.01.05 Non Formulary NICE TA212: Colorectal cancer (metastatic) - bevacizumab
Bivalirudin 02.08.01 Formulary NICE TA230 (July 2011): Bivalirudin for the treatment of ST-segment-elevation myocardial infarction
Boceprevir 05.03.03 Non Formulary NICE TA253: Hepatitis C (genotype 1) - boceprevir
Bortezomib Injection 08.01.05 Formulary NICE TA370 (December 2015): Bortezomib for previously untreated mantle lymphoma
Bortezomib Injection 08.01.05 Formulary NICE TA228 (July 2011) Bortezomib and thalidomide for the first-line treatment of multiple myeloma
Bortezomib Injection 08.01.05 Formulary NICE TA129 (October 2007): Bortezomib monotherapy for relapsed multiple myeloma
Botulinum toxin type A 04.07.04.02 Restricted Use NICE TA260: Migraine (chronic) - botulinum toxin type A
Cabazitaxel 08.01.05 Non Formulary NICE TA255: Prostate cancer - cabazitaxel
Canagliflozin 06.01.02.03 Formulary NICE TA315 (June 2014): Canagliflozin in combination therapy for treating type 2 diabetes
Capecitabine Tablets 08.01.03 Formulary NICE TA61: Colorectal cancer - capecitabine and tegafur uracil: guidance
Capecitabine Tablets 08.01.03 Formulary NICE TA191: Gastric cancer (advanced) - capecitabine
Capecitabine Tablets 08.01.03 Formulary NICE TA263: Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer
Carmustine 08.01.01 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Certolizumab Pegol 10.01.03 Restricted Use NICE TA445 (May 2017): Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Chlorpropamide 06.01.02.01 Non Formulary NICE CKS (July 2016): Diabetes - type 2
Ciclosporin 0.1% eye drops 11.08.01 Formulary NICE (TA369) Dec 2015: Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears
Cilostazol 02.06.04 Non Formulary NICE TA223 (May 2011): Cilostazol, naftidrofuryl oxalate, pentoxifylline, and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease
Cinacalcet 09.05.01.02 Restricted Use NICE TA117: Hyperparathyroidism - cinacalcet
Clopidogrel 02.09 Formulary NICE TA210 (December 2010): Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events
Colestyramine 02.12 Formulary NICE CG71 (July 2016): Familial hypercholesterolaemia: identification and management
Dabigatran Etexilate Capsules 02.08.02 Formulary NICE TA327(December 2014): Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Dabigatran Etexilate Capsules 02.08.02 Formulary NICE ESMN73 (May 2016): Reversal of the anticoagulant effect of dabigatran: idarucizumab
Dabigatran Etexilate Capsules 02.08.02 Formulary NICE TA249 (March 2012): Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation
Dabigatran Etexilate Capsules 02.08.02 Formulary NICE TA157 (September 2008): Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults
Dapagliflozin 06.01.02.03 Formulary NICE TA288 (June 2013): Dapagliflozin in combination therapy for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA418 (November 2016): Dapaglifozin in triple therapy for treating type 2 diabetes
Darvadstrocel suspension for injection 01.05.03 Non Formulary NICE TA556 (January 2019): Darvadstrocel for treating complex perianal fistulas in Crohn’s disease
Dasatinib 08.01.05 Formulary NICE TA425 (December 2016): Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Decitabine 08.01.03 Non Formulary NICE TA270: Leukaemia (acute myeloid ) - decitabine
Denosumab 06.06.02 Formulary NICE TA194: Bone loss (therapy-induced) in non-metastatic prostate cancer - denosumab: advice
Denosumab 06.06.02 Formulary NICE TA204: Osteoporotic fractures - denosumab
Denosumab 06.06.02 Formulary NICE TA265: Bone metastases from solid tumours - denosumab
Dexamethasone intravitreal implant 11.04.01 Non Formulary NICE TA229: Macular oedema (retinal vein occlusion) - dexamethasone
Dimethyl fumarate 08.02.04 Formulary NICE TA320 - Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis
Dimethyl Fumarate tablets 08.02.04 Restricted Use NICE TA475 (September 2017): Dimethyl fumarate for treating moderate to severe plaque psoriasis
Dipyridamole Modified Release 02.09 Formulary NICE (December 2010): Clopidogrel and modified- release dipyridamole for the prevention of occlusive vascular events
Docetaxel 08.01.05 Non Formulary NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
Docetaxel 08.01.05 Non Formulary NICE TA109: Breast cancer (early) - docetaxel
Doxazosin 02.05.04 Formulary NICE CG127 (November 2016): Hypertension in adults: diagnosis and management
Dronedarone 02.03.02 Formulary NICE TA197 (August 2010): Dronedarone for the treatment of non-permanent atrial fibrillation
Edoxaban 02.08.02 Formulary NICE TA355 (September 2015): Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation
Edoxaban 02.08.02 Formulary NICE TA 354 (August 2015): Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism
Efalizumab 13.05.03 Non Formulary NICE TA103: Psoriasis - efalizumab and etanercept
Eltrombopag 09.01.04 Non Formulary NICE TA205: Thrombocytopenic purpura - eltrombopag
Eluxadoline tablets 01.04.02 Formulary NICE TA471 (August 2017): Eluxadolone for treating irritable bowel syndrome with diarrhoea
Empagliflozin 06.01.02.03 Formulary NICE TA336 (March 2015): Empagliflozin in combination therapy for treating type 2 diabetes
Enzalutamide 08.03.04.02 Formulary NICE TA377 (January 2016): Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Enzalutamide 08.03.04.02 Formulary NICE TA316 (July 2014): Enzalutamide for metastatic hormone- relapsed prostate cancer previously treated with a docetaxel-containing regimen
Eptifibatide 02.09 Formulary NICE TA47 (March 2010): Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes (partially updated by CG94)
Eribulin 08.01.05 Non Formulary NICE TA250: Breast cancer (advanced) - eribulin
Erlotinib 08.01.05 Formulary NICE TA258 (June 2012): Erlotinib for the first line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
Erlotinib 08.01.05 Formulary NICE TA227 (June 2011): Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer
Etanercept 13.05.03 Restricted Use NICE TA103: Psoriasis - efalizumab and etanercept
Etanercept 10.01.03 Restricted Use NICE TA35: Arthritis (juvenile idiopathic) - etanercept
Etelcalcetide Injection 06.06.01 Restricted Use TA448 (June 2017): Etelcalcetide for treating secondart hyperparathyroidism
Everolimus 08.01.05 Non Formulary NICE TA342 (February 2017): Everolimus for advanced renal cell carcinoma after previous treatment
Evolocumab solution for injection 02.12 Formulary NICE TA394 (June 2016): Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Ezetimibe 02.12 Formulary NICE TA385 (February 2016): Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia
Febuxostat 10.01.04 Formulary NICE TA164: Febuxostat for the management of hyperuricaemia in people with gout
Fenofibrate 02.12 Formulary NICE CG181 (September 2016): Cardiovascular disease: risk assessment and reduction, including lipid modification
Fingolimod 08.02.04 Formulary NICE TA254 (April 2012): Fingolimod for the treatment of highly active relapsing - remitting mulitple sclerosis
Fludarabine Phosphate 08.01.03 Formulary NICE TA119: Leukaemia (lymphocytic) - fludarabine
Fludarabine Phosphate 08.01.03 Formulary NICE TA29: Leukaemia (lymphocytic) - fludarabine
Fulvestrant Injection 08.03.04.01 Non Formulary NICE TA239 (December 2011): Fulvestrant for the treatment of locally advanced or metastatic breast cancer
Gefitinib 08.01.05 Non Formulary NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
Gemcitabine Injection 08.01.03 Formulary NICE TA25: Pancreatic cancer - gemcitabine
Gemcitabine Injection 08.01.03 Formulary NICE TA116: Breast cancer - gemcitabine
Golimumab 10.01.03 Restricted Use NICE TA497 (January 2018): Golimumab for treating non-radiographic axial spondyloarthritis
Golimumab 10.01.03 Restricted Use NICE TA220 (April 2011): Golimumab for the treatment of psoriatic arthritis
Golimumab 10.01.03 Restricted Use NICE TA225 (June 2011): Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease modifying anti-rheumatic drugs
Hydralazine Hydrochloride 02.05.01 Formulary NICE CG108 (August 2010): Chronic Heart Failure in Adults: management
Ibrutinib 08.01.05 Formulary NICE (January 2017): Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
Imatinib 08.01.05 Formulary NICE TA326 (November 2014): Imatinib for the adjuvant treatment of gastrointestional stromal tumours
Imatinib 08.01.05 Formulary NICE TA70: Leukaemia (chronic myeloid) - imatinib
Imatinib 08.01.05 Formulary NICE TA209: Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib
Imatinib 08.01.05 Formulary NICE TA196: Gastrointestinal stromal tumours - imatinib (adjuvant)
Imatinib 08.01.05 Formulary NICE TA425 (December 2016): Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Inositol Nicotinate 02.06.04 Non Formulary NICE TA223 (May 2011): Cilostazol, Naftidrofuryl oxalate, Pentoxifylline and Inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease
Ipilimumab 08.01.05 Non Formulary NICE TA268: Melanoma (stage III or IV) - ipilimumab
Irinotecan Hydrochloride 08.01.05 Non Formulary NICE TA440 (April 2017): Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine
Ivabradine 02.06.03 Restricted Use NICE TA267 (November 2012): Ivabradine for treating chronic heart failure
Ixekizumab solution for injection 13.05.03 Restricted Use NICE TA442 (April 2017) Ixekizumab for treating moderate to severe plaque psoriasis
Ixekizumab solution for injection 13.05.03 Restricted Use NICE TA 537 (August 2018): Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDS
Ixekizumab solution for injection 13.05.03 Restricted Use NICE TA537 (August 2018): Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
Lapatinib 08.01.05 Non Formulary NICE TA257: Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor)
Lenalidomide 08.02.04 Formulary NICE TA171: Multiple myeloma
Lenalidomide 08.02.04 Formulary NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
Levocetirizine Hydrochloride 03.04.01 Non Formulary NICE CKS (October 2015): Allergic Rhinitis
Lidocaine 5% Medicated Plaster 15.02 Non Formulary NICE CG173 (November 2013): Neuropathic pain in adults: pharmacological management in non-specialist settings
Linaclotide 01.06 Restricted Use NICE CG61 (Feb 2008): Irritable bowel syndrome in adults: disgnosis and management
Lubiprostone 01.06 Formulary NICE TA318 - Lubiprostone for treating chronic idiopathic constipation
Lumacaftor 200mg and Ivacaftor 125mg 03.07 Non Formulary NICE TA398 (July 2016): Lumacaftor- Ivacaftor for treating cystic fybrosis homozygous for the F508del mutation
Mannitol 03.07 Formulary NICE TA266 (November 2012): Mannitol dry powder for inhalation for treating cystic fibrosis
Mannitol Dry Powder for Inhalation 03.07 Non Formulary NICE TA266: Cystic fibrosis - mannitol dry powder for inhalation
Methotrexate Intramuscular Injection 07.01 Restricted Use NICE CG154: Ectopic pregnancy and miscarriage
Methyldopa 02.05.02 Formulary NICE CG107 (August 2010): Hypertension in pregnancy: diagnosis and management
Methylnaltrexone 01.06.06 Restricted Use NICE TA277: Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal)
Mifamurtide 08.02.04 Non Formulary NICE TA235: Osteosarcoma - mifamurtide
Mirabegron m/r Tablets 07.04.02 Formulary NICE TA290 (June 2013): MIrabegron for treating symptoms of overactive bladder
Misoprostol 07.01.01 Formulary NICE CG154: Ectopic pregnancy and miscarriage
Moxisylyte 02.06.04 Non Formulary NICE CKS (April 2014): Raynaud’s Phenomenon
Moxonidine 02.05.02 Restricted Use NICE CG127 (Novamber 2016): Hypertension in adults: diagnosis and management
Naloxegol 01.06.06 Restricted Use NICE TA345 (July 2015) Naloxegol for treating opioid-induced constipation
Naproxen with Esomeprazole 10.01.01 Non Formulary NICE CKS (November 2012): Dyspepsia - proven GORD
Nilotinib 08.01.05 Formulary NICE TA425 (December 2016): Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Obeticholic acid tablets 01.09 Restricted Use NICE TA443 (April 2017): Obeticolic acid for treating primary biliary cholangitis
Ofatumumab 08.02.03 Non Formulary NICE TA202: Chronic lymphocytic leukaemia
Omalizumab 03.04.02 Restricted Use NICE TA278 (April 2013): Omalizumab for treating severe persistant allergic asthma
Omalizumab 03.04.02 Restricted Use NICE TA339 (June 2015): Omalizumab for previously treated chronic spontaneous urticaria
Panitumumab 08.01.05 Non Formulary NICE TA240: Colorectal cancer (metastatic) - panitumumab
Panobinostat Capsules 08.01.05 Formulary NICE TA380 (January 2016): Panobinostat for treating multiple myeloma after at least two previous treatments
Pazopanib 08.01.05 Non Formulary NICE TA215: Renal cell carcinoma (first line metastatic) - pazopanib
Pemetrexed 08.01.03 Non Formulary NICE TA135: Mesothelioma - pemetrexed disodium
Pemetrexed 08.01.03 Non Formulary NICE TA124: Lung cancer (non-small cell)
Pemetrexed 08.01.03 Non Formulary NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed
Pemetrexed 08.01.03 Non Formulary NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance)
Pentoxifylline 02.06.04 Non Formulary NICE TA223 (May 2011): Cilostazol, Naftidrofuryl Oxalate, Pentoxifylline and Inositol Nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease
Pimecrolimus 1% cream 13.05.03 Non Formulary NICE TA82: Atopic dermatitis (eczema) - pimecrolimus and tacrolimus
Pirfenidone 03.11 Formulary NICE TA504 (February 2018): Pirfenadone for treating idiopathic pulmonary fibrosis
Pomalidomide 08.02.04 Formulary NICE (January 2017): Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
Ponatinib tablets 08.01.05 Formulary NICE TA451 (June 2017): Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
Prasugrel 02.09 Formulary NICE TA317 (July 2014): Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes
Prucalopride 01.06.07 Restricted Use NICE TA211: Prucalopride for the treatment of chronic constipation in women
Ranibizumab 11.08.02 Non Formulary NICE TA274: Macular oedema (diabetic) - ranibizumab
Retigabine 04.08.01 Non Formulary NICE TA232: Epilepsy (partial) - retigabine (adjuvant)
RIfaximin 550mg tablets 05.01.07 Restricted Use NICE TA337 (March 2015): Rifaximin for preventing episodes of overt hepatic encephalopathy
Riluzole 04.09.03 Restricted Use NICE TA20 (January 2001): Guidance on the use of Riluzole (Rilutek) for the treatment of Motor Neurone Disease
Risperidone 04.02.01 Formulary NICE CG158: Conduct disorders in children and young people
Rituximab 08.02.03 Restricted Use NICE TA226: Lymphoma (follicular non-Hodgkins) - rituximab
Rituximab 08.02.03 Restricted Use NICE TA243: Follicular lymphoma - rituximab (review)
Rituximab 08.02.03 Restricted Use NICE TA174: Leukaemia (chronic lymphocytic, first line) - rituximab
Rituximab 08.02.03 Restricted Use NICE TA65: Non-Hodgkins lymphoma - rituximab
Rituximab 08.02.03 Restricted Use NICE TA137: Lymphoma (follicular non-Hodgkins) - rituximab
Rivaroxaban Tablets 02.08.02 Formulary NICE TA256 (May 2012): Rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation
Rivaroxaban Tablets 02.08.02 Formulary NICE TA261 (July 2012): Rivaroxaban for the treatment of deep-vein thrombosis and prevention of recurrent deep-vein thrombosis and pulmonary embolism
Rivaroxaban Tablets 02.08.02 Formulary NICE TA287 (June 2013): Rivaroxiban for treating pulmonary embolism and preventing recurrent venous thromboembolism
Rivaroxaban Tablets 02.08.02 Formulary NICE TA170 (April 2009): Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults
Rivaroxaban Tablets 02.08.02 Formulary NICE TA335 (March 2015): Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome
Roflumilast 03.03.03 Formulary NICE TA2461 (July 2017): Roflumilast for treating chronic obstructive pulmonary disease
Romiplostim 09.01.04 Restricted Use NICE TA221: Thrombocytopenic purpura - romiplostim
Ruxolitinib 08.01.05 Restricted Use NICE TA386 (March 2016) Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
Sacubitril Valsartan 02.05.05 Restricted Use NICE TA388 (April 2016): Sacubitril Valsartan for treating symptomatic chronic heart failure with reduced ejection fraction
Sarilumab solution for injection 10.01.03 Restricted Use NICE TA485 (November 2017): Sarilumab for moderate to severe rheumatoid arthritis
Secukinumab 13.05.03 Restricted Use NICE TA445 (May 2017): Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Secukinumab 13.05.03 Restricted Use NICE TA407 (September 2016): Secinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
Secukinumab 13.05.03 Restricted Use NICE 350 (July 2015): Secukinumab for treating moderate to severe plaque psoriasis
Sorafenib 08.01.05 Non Formulary NICE TA178: Renal cell carcinoma
Sorafenib 08.01.05 Non Formulary NICE TA189: Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line)
Sunitinib 08.01.05 Non Formulary NICE TA178: Renal cell carcinoma
Sunitinib 08.01.05 Non Formulary NICE TA169: Renal cell carcinoma - sunitinib
Sunitinib 08.01.05 Non Formulary NICE TA179: Gastrointestinal stromal tumours - sunitinib
Tacrolimus 0.03% Ointment 13.05.03 Restricted Use NICE TA82: Atopic dermatitis (eczema) - pimecrolimus and tacrolimus
Tacrolimus 0.1% Ointment 13.05.03 Restricted Use NICE TA82: Atopic dermatitis (eczema) - pimecrolimus and tacrolimus
Tegafur with Uracil 08.01.03 Non Formulary NICE TA61: Colorectal cancer - capecitabine and tegafur uracil: guidance
Telaprevir 05.03.03 Non Formulary NICE TA252: Hepatitis C (genotype 1) - telaprevir
Temozolomide 08.01.05 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Temozolomide 08.01.05 Non Formulary NICE TA23: Brain cancer - temozolomide
Temsirolimus 08.01.05 Non Formulary NICE TA178: Renal cell carcinoma
Temsirolimus 08.01.05 Non Formulary NICE TA207: Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal)
Terlipressin 06.05.02 Formulary NICE CG141: Acute upper GI bleeding
Thalidomide 08.02.04 Formulary NICE TA228: Multiple myeloma (first line) - bortezomib and thalidomide
Ticagrelor 02.09 Formulary NICE TA236 (October 2011): Ticagrelor for the treatment of acute coronary syndromes
Ticagrelor 02.09 Formulary NICE TA420 (December 2016): Ticagrelor for preventing atherothrombotic events after myocardial infarction
Tirofiban 02.09 Formulary NICE TA47 (March 2010): Guidance on the use of glycoprotein IIb/III3 inhibitors in the treatment of acute coronary syndromes (partially updated by CG94)
Tocilizumab 10.01.03 Restricted Use NICE TA238 (December 2011): Tocilizumab for the treatment of systemic juvenile idiopathic arthritis
Tocilizumab 10.01.03 Restricted Use NICE TA247 (February 2012): Tocilizumab for the treatment of rheumatoid arthritis
Tofacitinib Tablets 10.01.03 Formulary NICE TA480 (October 2017): Tofacitinib for moderate to severe rheumatoid arthritis
Tofacitinib tablets 13.05.03 Restricted Use NICE TA543 (October 2018) Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
Tofacitinib tablets 13.05.03 Restricted Use NICE TA480 (October 2017): Tofacitinib for moderate to severe rheumatoid arthritis
Tolvaptan 06.05.02 Restricted Use NICE TA358 (October 2015): Tolvaptan for treating autosomal dominant polycystic kidney disease
Topotecan 08.01.05 Non Formulary NICE TA184 (November 2009): Topotecan for the treatment of relapsed small-cell lung cancer
Topotecan 08.01.05 Non Formulary NICE TA183 (October 2009) : Topotecan for the treatment of recurrant and stage IVB cervical cancer
Tranexamic Acid 02.11 Formulary NICE CG44 (August 2016): Heave Menstrual Bleeding: assessment and management
Trastuzumab 08.01.05 Non Formulary NICE TA34: Breast cancer - trastuzumab
Trastuzumab 08.01.05 Non Formulary NICE TA107: Breast cancer (early) - trastuzumab
Trastuzumab 08.01.05 Non Formulary NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
Trastuzumab 08.01.05 Non Formulary NICE TA257: Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor)
Ustekinumab 13.05.03 Formulary NICE TA340: Ustekinumab for treating active psoriatic arthritis
Ustekinumab 13.05.03 Formulary NICE TA456 (July 2017): Ustekinumab for moderately to severly active Crohn’s disease after previous treatment
Ustekinumab 13.05.03 Formulary NICE TA180: Ustekinumab for the treatment of adults with moderate to severe psoriasis
Varenicline 04.10.02 Formulary NICE TA123: Smoking cessation - varenicline
Vedolizumab 01.05.03 Restricted Use NICE TA352 (August 2015): Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy
Vedolizumab 01.05.03 Restricted Use NICE TA342 (June 2015): Vedolizumab for treating moderately to severely active ulcerative colitis
Vemurafenib 08.01.05 Non Formulary NICE TA269: Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib
Vinflunine 08.01.04 Non Formulary NICE TA272: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine
Vitamin B Tablets (Compound Strong) 09.06.02 Formulary NICE CG115 (February 2011) Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependance
Vitamin B Tablets (Compound Strong) 09.06.02 Formulary NICE CG100 (April 2017): Alcohol-use disorders: diagnosis and management of physical complications
Vitamin B Tablets (Compound) 09.06.02 Non Formulary NICE CG100: Alcohol-use disorders: disgnosis and management of physical complications
Tameside and Glossop Integrated Care